Lupin, Matrix face antitrust probe in EU

09 Jul 2009 Evaluate
`

The bad times that the Indian pharmaceutical industry has been facing overseas are about to turn worse. Lupin Ltd, Matrix Laboratories and Niche Generics, the UK subsidiary of Unichem Laboratories, may face antitrust investigations by the European Union for delaying the entry into the market of generic versions of a hypertension drug.

 

The European Union’s antitrust regulator, the European Commission, said the three Indian companies, along with France’s Les Laboratories Servier, Israel-based Teva Laboratories and Krka Group, had entered into agreements to delay the entry of generic versions of Perindopril, on which Laboratories Servier had the patent. The market in Europe for Perindopril is worth $400 million.

 

The drug regulators in the US and Europe have in recent times raised question marks over the practices followed by some big Indian drug makers. The European Commission had started these investigations 18 months ago, following complaints that non-branded drugs were slow coming into the market because generic drug makers were teaming with patent holding companies to delay launches.

crackcrack

Lupin Share Price

2147.55 -14.65 (-0.68%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.